5-Oxo-6-isopropyl-5,6-dihydropyrido<2,3-d>pyridazin | 66135-74-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Oxo-6-isopropyl-5,6-dihydropyrido<2,3-d>pyridazin
• 英文别名: 6-isopropyl-6H-pyrido[2,3-d]pyridazin-5-one；6-Propan-2-ylpyrido[2,3-d]pyridazin-5-one
• CAS: 66135-74-8
• 化学式: C₁₀H₁₁N₃O
• 分子量: 189.217
• InChiKey: JDXLCEUBZAGBLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• Oxadiazole transient receptor potential channel inhibitors
  申请人：Genentech, Inc.

  公开号：US10710994B2

  公开（公告）日：2020-07-14

  The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  本发明涉及式 I 的化合物： 及其药学上可接受的盐，其中 A、X、R1、R4 和 n 如本文所定义。此外，本发明还涉及式 I 化合物的制造方法和使用方法，以及含有此类化合物的药物组合物。这些化合物可用于治疗由 TRPA1 介导的疾病和病症，如疼痛。
• OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
  申请人：Genentech, Inc.

  公开号：US20200308161A1

  公开（公告）日：2020-10-01

  The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R 1 , R 4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
• US9931407B2
  申请人：——

  公开号：US9931407B2

  公开（公告）日：2018-04-03
• [EN] SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME<br/>[FR] CONJUGUÉS DE MÉDICAMENT À BASE DE SILICIUM ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BLINKBIO INC

  公开号：WO2016183359A1

  公开（公告）日：2016-11-17

  Described herein are silicon based conjugates capable of delivering one or more pay load moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more pay load moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.